Tandem Diabetes Reports Mixed Q4 Earnings, Issues Better Than Expected FY22 Outlook

Tandem Diabetes Care Inc TNDM reported Q4 sales reached $209.9 million, +25% Y/Y, beating the consensus of $199.12 million.

  • The Company posted EPS of $0.16, down from $0.22 a year ago, and missed the Wall Street estimate of $0.21.
  • Worldwide pump shipments increased 15% Y/Y to 37,585.
  • The gross margin remained almost unchanged at 54%, and the operating margin decreased from 11% to 6%.
  • Tandem Diabetes ended Q3 with cash, cash equivalents, and short-term investments of $595.0 million.
  • Guidance: Tandem forecasts FY22 sales of $845 million - $860 million, representing a Y/Y growth of 20% - 22%, beating the consensus of $827.23 million.
  • The guidance includes sales outside the U.S. of approximately $215 million to $220 million.
  • The gross margin is estimated to be around 54%, with an adjusted EBITDA margin of 14% - 15%.
  • Price Action: TNDM shares traded 2% lower at $104.03 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!